Table 1.
Open in new tab

Clinical and laboratory characteristics of the 2 groups (arm A and arm B) of 69 thyroidectomized patients with thyroid cancer

CharacteristicArm Aa
(n = 33)		Arm Bb
(n = 36)		P value
Age (mean ± SD) years42.6 ± 11.347.2 ± 10.9.09
Sex (female: male)22:1126:10.81
BMI (kg/m2)30.4 ± 631.2 ± 6.5.60
Thyroid cancer type (n)
Papillary thyroid cancer2831.52
Follicular thyroid cancer12
Oncocytic thyroid cancer01
Medullary thyroid cancer42
Current thyroid cancer status (n)
Excellent response1822.83
Indeterminate response66
Biochemically incomplete53
Structurally incomplete45
L-T4 dose before Ramadan (µg/day), mean ± SD141.8 ± 28.7137.1 ± 42.5.59
TSH before Ramadan (mU/L) mean ± SD1.94 ± 2.02.37 ± 3.7.69
No. of patients with other comorbidities
(DM, HTN, dyslipidemia, others)		10/3314/36.45
CharacteristicArm Aa
(n = 33)		Arm Bb
(n = 36)		P value
Age (mean ± SD) years42.6 ± 11.347.2 ± 10.9.09
Sex (female: male)22:1126:10.81
BMI (kg/m2)30.4 ± 631.2 ± 6.5.60
Thyroid cancer type (n)
Papillary thyroid cancer2831.52
Follicular thyroid cancer12
Oncocytic thyroid cancer01
Medullary thyroid cancer42
Current thyroid cancer status (n)
Excellent response1822.83
Indeterminate response66
Biochemically incomplete53
Structurally incomplete45
L-T4 dose before Ramadan (µg/day), mean ± SD141.8 ± 28.7137.1 ± 42.5.59
TSH before Ramadan (mU/L) mean ± SD1.94 ± 2.02.37 ± 3.7.69
No. of patients with other comorbidities
(DM, HTN, dyslipidemia, others)		10/3314/36.45

Abbreviations: BMI, body mass index; DM, diabetes mellitus; HTN, hypertension; LT-4, levothyroxine; TSH, thyrotropin.

aArm A: continued on the same LT-4 dose before the fasting month and broke their fasting immediately.

bArm B: similar to arm A, but the LT-4 dose was increased by 25 µg if their pre-Ramadan dose was ≤150 µg/day and by 50 µg if the L-thyroxine daily dose was >150 µg daily

Table 1.
Open in new tab

Clinical and laboratory characteristics of the 2 groups (arm A and arm B) of 69 thyroidectomized patients with thyroid cancer

CharacteristicArm Aa
(n = 33)		Arm Bb
(n = 36)		P value
Age (mean ± SD) years42.6 ± 11.347.2 ± 10.9.09
Sex (female: male)22:1126:10.81
BMI (kg/m2)30.4 ± 631.2 ± 6.5.60
Thyroid cancer type (n)
Papillary thyroid cancer2831.52
Follicular thyroid cancer12
Oncocytic thyroid cancer01
Medullary thyroid cancer42
Current thyroid cancer status (n)
Excellent response1822.83
Indeterminate response66
Biochemically incomplete53
Structurally incomplete45
L-T4 dose before Ramadan (µg/day), mean ± SD141.8 ± 28.7137.1 ± 42.5.59
TSH before Ramadan (mU/L) mean ± SD1.94 ± 2.02.37 ± 3.7.69
No. of patients with other comorbidities
(DM, HTN, dyslipidemia, others)		10/3314/36.45
CharacteristicArm Aa
(n = 33)		Arm Bb
(n = 36)		P value
Age (mean ± SD) years42.6 ± 11.347.2 ± 10.9.09
Sex (female: male)22:1126:10.81
BMI (kg/m2)30.4 ± 631.2 ± 6.5.60
Thyroid cancer type (n)
Papillary thyroid cancer2831.52
Follicular thyroid cancer12
Oncocytic thyroid cancer01
Medullary thyroid cancer42
Current thyroid cancer status (n)
Excellent response1822.83
Indeterminate response66
Biochemically incomplete53
Structurally incomplete45
L-T4 dose before Ramadan (µg/day), mean ± SD141.8 ± 28.7137.1 ± 42.5.59
TSH before Ramadan (mU/L) mean ± SD1.94 ± 2.02.37 ± 3.7.69
No. of patients with other comorbidities
(DM, HTN, dyslipidemia, others)		10/3314/36.45

Abbreviations: BMI, body mass index; DM, diabetes mellitus; HTN, hypertension; LT-4, levothyroxine; TSH, thyrotropin.

aArm A: continued on the same LT-4 dose before the fasting month and broke their fasting immediately.

bArm B: similar to arm A, but the LT-4 dose was increased by 25 µg if their pre-Ramadan dose was ≤150 µg/day and by 50 µg if the L-thyroxine daily dose was >150 µg daily

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close